OUS_Viatris_Logo_Verti_RGB

This promotional video has been commissioned and funded by Viatris and developed in partnership with GuidelinesSee below for full disclaimer.

Products and brand names are mentioned.

Intended for UK healthcare professionals.

View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.

 

In this short video, Professor Serge Rozenberg (Professor of Gynecology, Free University of Brussels), answers the following questions:

  • What is hormone replacement therapy (HRT) and its main purpose?
  • Does it matter which progestogen you choose for this purpose?
  • Explain the differential impact of the type of progestogen: breast cancer, venous thromboembolism (VTE) risks, and side effects profile.

Read the prescribing HRT containing dydrogesterone algorithm here

Watch the on demand webinar with an overview and focus on progestogens here

This promotional video has been commissioned and funded by Viatris and developed in partnership with Guidelines. Viatris commissioned the speaker, and paid their honorarium. The views and opinions of the presenters are not necessarily those of Viatris, Guidelines, its publisher, advisers, or advertisers. No part of this webinar may be reproduced in any form without the permission of the publisher.

FEM-2021-0361

Date of preparation: March 2022